Veracyte Q4 GAAP net income jumps 8.1x to USD 41.1 million

Veracyte reported Q4 2025 total revenue of USD 140.6 million (+19%), including testing revenue of USD 135.8 million (+21%), product revenue of USD 3.8 million (+27%) and biopharmaceutical and other revenue of USD 1.0 million, which declined due to the restructuring and liquidation proceedings of Veracyte SAS. Q4 2025 GAAP net income was USD 41.1 million (29.3% of revenue) and adjusted EBITDA was USD 42.3 million (30.1% of revenue), with USD 52.6 million of cash generated from operations. Q4 total volume was 48,019 tests (+16%), including testing volume of 45,516 tests (+16%); Decipher revenue was USD 85.6 million (+27%) on approximately 27,200 tests (+21%), and Afirma revenue was USD 47.9 million (+16%) on approximately 18,250 tests (+12%). For FY 2025, Veracyte posted total revenue of USD 517.1 million (+16%) and testing revenue of USD 493.2 million (+18%), with GAAP net income of USD 66.4 million (12.8% of revenue), adjusted EBITDA of USD 142.5 million (27.6% of revenue), and USD 136.3 million of cash from operations; cash, cash equivalents and short-term investments were USD 412.9 million at year-end. The company reiterated FY 2026 total revenue guidance of USD 570 million to USD 582 million (10% to 13% growth) and said adjusted EBITDA margin is expected to be approximately 25%. Business updates included more than 15 abstracts featuring Decipher Prostate and Decipher Bladder slated for ASCO GU, TrueMRD MIBC’s inclusion in the HCRN GU 20-444 bladder-sparing trial, and completion of the transition of all Afirma samples to the v2 transcriptome to support efficiency and future launches such as Prosigna as an LDT; management also cited planned 2026 launches of Prosigna (as an LDT) and TrueMRD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225137453) on February 25, 2026, and is solely responsible for the information contained therein.